Cited by 1,826Advanced Radiotherapy TechniquesRadiation Therapy and DosimetryEffects of Radiation Exposure

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Use of Normal Tissue Complication Probability Models in the Clinic

Open access

Marks, Lawrence B., Yorke, Ellen D., Jackson, Andrew, Ten Haken, Randall K., Constine, Louis S., Eisbruch, Avraham, Bentzen, Søren M., Nam, Jiho, Deasy, Joseph O.·2010·International Journal of Radiation Oncology*Biology*Physics

DOI 10.1016/j.ijrobp.2009.07.1754PMC PMC4041542

Open this paper in CoChat — free account Open PDF

Abstract

The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) review summarizes the currently available three-dimensional dose/volume/outcome data to update and refine the normal tissue dose/volume tolerance guidelines provided by the classic Emami et al. paper published in 1991. A "clinician's view" on using the QUANTEC information in a responsible manner is presented along with a description of the most commonly used normal tissue complication probability (NTCP) models. A summary of organ-specific dose/volume/outcome data, based on the QUANTEC reviews, is included.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2009.07.1754

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
Trotti, A., Colevas, A. D., Setser, A., Rusch, V. W., Jaques, D. P., Budach, V., Langer, C. J., Murphy, B. A., Cumberlin, R. L., & Coleman, C. N. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
Fitting of normal tissue tolerance data to an analytic function
Burman, C. M., Kutcher, G. J., Emami, B., & Goitein, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90172-z · Cited by 1,251
Reporting and analyzing dose distributions: A concept of equivalent uniform dose
Niemierko, A. (1997) · Medical Physics · doi:10.1118/1.598063 · Cited by 1,231
Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
Graham, M. V., Purdy, J. A., Emami, B., Harms, W. B., Bosch, W. R., Lockett, M. A., & Perez, C. A. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00183-2 · Cited by 1,221
Complication Probability as Assessed from Dose-Volume Histograms
Lyman, J. T. (1985) · Radiation Research · doi:10.2307/3576626 · Cited by 1,160
Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations
Kutcher, G. J., Burman, C. M., Brewster, L. J., Goitein, M., & Mohan, R. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90173-2 · Cited by 560
Complication Probability as Assessed from Dose-Volume Histograms
Lyman, J. T. (1985) · Radiation Research Supplement · doi:10.2307/3583506 · Cited by 537
The Linear-Quadratic Model Is Inappropriate to Model High Dose per Fraction Effects in Radiosurgery
Kirkpatrick, J. P., Meyer, J. J., & Marks, L. B. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.04.005 · Cited by 519
Self-citation
Treatment volume and tissue tolerance
Withers, H. R., Taylor, J. M. G., & Maciejewski, B. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90098-3 · Cited by 446

Flagged first, then by citations

Show all 30 references

1 of the 30 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Jolles, 1939, Area factor in skin reaction, Br Emp Cancer Campaign Rep, 16
Niemierko, 1999, A generalized concept of equivalent uniform dose (EUD), Med Phys, 26, 1100

Sorted by citations

Items 101–200 of 1,000

SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review
Armstrong, N., Bahl, A. K., Pinkawa, M., Ryder, S., Ahmadu, C., Ross, J., Bhattacharyya, S., Woodward, E. J., Battaglia, S., Binns, J., et al. (2021) · Urology · doi:10.1016/j.urology.2021.05.013 · Cited by 70
Delayed primary excision with subsequent modification of radiotherapy dose for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee
Rodeberg, D. A., Wharam, M. D., Lyden, E. R., Stoner, J. A., Brown, K. L. B., Wolden, S. L., Paidas, C. N., Donaldson, S. S., Hawkins, D. S., Spunt, S. L., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29351 · Cited by 70
Small Bowel Dose Parameters Predicting Grade ≥3 Acute Toxicity in Rectal Cancer Patients Treated With Neoadjuvant Chemoradiation: An Independent Validation Study Comparing Peritoneal Space Versus Small Bowel Loop Contouring Techniques
Banerjee, R. N., Chakraborty, S., Nygren, I., & Sinha, R. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.09.036 · Cited by 68
Complication Probability Models for Radiation-Induced Heart Valvular Dysfunction: Do Heart-Lung Interactions Play a Role?
Cella, L., Palma, G., Deasy, J. O., Oh, J. H., Liuzzi, R., D’Avino, V., Conson, M., Pugliese, N., Picardi, M., Salvatore, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111753 · Cited by 70
Self-citation
Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
Geenen, L., Nonnekens, J., Konijnenberg, M., Baatout, S., de Jong, M., & Aerts, A. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.06.006 · Cited by 67
Breathing adapted radiation therapy in comparison with prone position to reduce the doses to the heart, left anterior descending coronary artery, and contralateral breast in whole breast radiation therapy
Verhoeven, K., Sweldens, C., Petillion, S., Laenen, A., Peeters, S., Janssen, H., Limbergen, E. V., & Weltens, C. G. (2013) · Practical Radiation Oncology · doi:10.1016/j.prro.2013.07.005 · Cited by 68
DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use
Klingler, M., Summer, D., Rangger, C. A., Haubner, R., Foster, J., Sosabowski, J. K., Decristoforo, C., Virgolini, I. J., & von Guggenberg, E. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.221283 · Cited by 64
“In radiation therapy, doses of less than 45 Gy are generally accepted for the stomach without unacceptable complications (28).”
Background
Recommendations for the Use of Radiotherapy in Nodal Lymphoma
Hoskin, P., Díez, P., Williams, M. V., Lucraft, H. H., & Bayne, M. (2012) · Clinical Oncology · doi:10.1016/j.clon.2012.07.011 · Cited by 63
Dose reduction to organs at risk with deep-inspiration breath-hold during right breast radiotherapy: a treatment planning study
Pandeli, C., Smyth, L. M. L., David, S., & See, A. W. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1430-x · Cited by 69
“The dose-volume objectives for the lungs and heart were aligned to QUANTEC guidelines as follows [17]; lung V20Gy < 30% and mean dose <20Gy, heart V30Gy < Pandeli et al.”
Method
Deep Learning–Based Dose Prediction for Automated, Individualized Quality Assurance of Head and Neck Radiation Therapy Plans
Gronberg, M., Beadle, B. M., Garden, A. S., Skinner, H. D., Gay, S., Netherton, T., Cao, W., Cardenas, C. E., Chung, C., Fuentes, D., et al. (2023) · Practical Radiation Oncology · doi:10.1016/j.prro.2022.12.003 · Cited by 62
“7,8 Meeting planning goals indicates a certain level of plan safety, but not optimality.”
Background
Effect of Dosimetric Factors on Occurrence and Volume of Temporal Lobe Necrosis Following Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma: A Case-Control Study
Zhou, X., Ou, X., Xu, T., Wang, X., Shen, C., Ding, J., & Hu, C. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.05.036 · Cited by 61
“The quantitative analysis of normal tissue effects in the clinic study also found the following doseresponse relationship in the brain, that is, that the incidence of radionecrosis rises from 3% with a dose of <60 Gy to 5% with a dose of 72 Gy and to 10% with 90 Gy (29).”
Background
Normal tissue complication probability (NTCP) parameters for breast fibrosis: Pooled results from two randomised trials
Mukesh, M. B., Harris, E., Collette, S., Coles, C. E., Bartelink, H. G. M. M., Wilkinson, J. S., Evans, P., Graham, P., Haviland, J., Poortmans, P. M., et al. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.07.006 · Cited by 61
“More recently, Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) articles summarised the quantitative effects of RT dose and treatment volume on late normal tissue complications [3].”
Method
Intensity-modulated radiation therapy for nasopharyngeal carcinoma: a review
Wang, T. J. C., Riaz, N., Cheng, S. K., Lu, J. J., & Lee, N. Y. (2012) · Journal of Radiation Oncology · doi:10.1007/s13566-012-0020-4 · Cited by 60
“The Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) provides recent data behind normal tissue complication probabilities [42].”
Background
Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress
Cuneo, K. C., Morgan, M. A., Davis, M. A., Parcels, L. A., Parcels, J., Karnak, D. M., Ryan, C., Liu, N., Maybaum, J., & Lawrence, T. S. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.01.028 · Cited by 60
Introducing Proton Track-End Objectives in Intensity Modulated Proton Therapy Optimization to Reduce Linear Energy Transfer and Relative Biological Effectiveness in Critical Structures
Tranéus, E., & Ödén, J. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.10.031 · Cited by 60
Dosimetric impact of deep learning-based CT auto-segmentation on radiation therapy treatment planning for prostate cancer
Kawula, M., Purice, D., Li, M., Vivar, G., Ahmadi, S., Parodi, K., Belka, C., Landry, G., & Kurz, C. (2022) · Radiation Oncology · doi:10.1186/s13014-022-01985-9 · Cited by 66
“Settings were chosen using the expert segmentation such that a PTV coverage of at least V 95% = 100% was achieved (no normalization was applied after optimization), while dose to OARs was below the recommendations of the QUANTEC report [22].”
Method
Carbon Ion Reirradiation for Recurrent Head and Neck Cancer: A Single-Institutional Experience
Held, T., Windisch, P. Y., Akbaba, S., Lang, K., Shafie, R. A. E., Bernhardt, D., Plinkert, P. K., Kargus, S., Rieken, S., Herfarth, K. K., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.07.021 · Cited by 58
Texture analysis as a predictor of radiation-induced xerostomia in head and neck patients undergoing IMRT
Nardone, V., Tini, P., Nioche, C., Mazzei, M. A., Carfagno, T., Battaglia, G., Pastina, P., Grassi, R., Sebaste, L., & Pirtoli, L. (2018) · La radiologia medica · doi:10.1007/s11547-017-0850-7 · Cited by 58
“induced xerostomia due to the sensitivity and specificity of normal tissue complication probability (NTCP) models at the clinic [15].”
Background
203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer
Li, M., Sagastume, E. A., Lee, D., McAlister, D. R., DeGraffenreid, A. J., Olewine, K. R., Graves, S. A., Copping, R., Mirzadeh, S., Zimmerman, B. E., et al. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200727190423 · Cited by 58
Time evolution of regional CT density changes in normal lung after IMRT for NSCLC
Bernchou, U., Schytte, T., Bertelsen, A. S., Bentzen, S. M., Hansen, O., & Brink, C. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.08.041 · Cited by 57
“Furthermore, even in asymptomatic patients, radiological changes could potentially reflect a lower capacity to deal with future cardiopulmonary stress [8].”
BackgroundSelf-citation
Fucoidan Inhibits Radiation-Induced Pneumonitis and Lung Fibrosis by Reducing Inflammatory Cytokine Expression in Lung Tissues
Yu, H., Ko, E. C., Chang, C., Yuan, K. S., Wu, A. T. H., Shan, Y., & Wu, S. (2018) · Marine Drugs · doi:10.3390/md16100392 · Cited by 57
Pseudo-CT Generation for MRI-Only Radiation Therapy Treatment Planning: Comparison Among Patch-Based, Atlas-Based, and Bulk Density Methods
Largent, A., Barateau, A., Nunes, J., Lafond, C., Greer, P. B., Dowling, J., Saint‐Jalmes, H., Acosta, O., & de Crevoisier, R. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.10.002 · Cited by 57
Clinical and epidemiological observations on individual radiation sensitivity and susceptibility
Seibold, P., Auvinen, A., Averbeck, D., Bourguignon, M., Hartikainen, J. M., Hoeschen, C., Laurent, O., Noël, G., Sabatier, L., Salomaa, S., et al. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1665209 · Cited by 56
“However, it is still estimated that up to 20% of the cancer patients develop radiotherapy-related adverse effects of grade 2 or higher, with about 5% experiencing grade 3 or 4 toxicities (e.g. Marks et al. 2010).”
Background
Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer
Hiroshima, Y., Fukumitsu, N., Saito, T., Numajiri, H., Murofushi, K. N., Ohnishi, K., Nonaka, T., Ishikawa, H., Okumura, T., & Sakurai, H. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.03.012 · Cited by 55
Real-time, volumetric imaging of radiation dose delivery deep into the liver during cancer treatment
Zhang, W., Oraiqat, I. M., Litzenberg, D. W., Chang, K., Hadley, S. W., Sunbul, N. B., Matuszak, M. M., Tichacek, C. J., Moros, E. G., Carson, P. L., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01593-8 · Cited by 55
“Moreover, dose escalation in many diseases is limited by adjacent normal tissue radiosensitivity 16,17 .”
Background
Dose-Response Modeling of the Visual Pathway Tolerance to Single-Fraction and Hypofractionated Stereotactic Radiosurgery
Hiniker, S. M., Modlin, L. A., Choi, C. Y. H., Atalar, B., Seiger, K., Binkley, M. S., Harris, J. P., Liao, Y. J., Fischbein, N. J., Wang, L., et al. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.11.008 · Cited by 55
Long-Term Results of Stereotactic Radiosurgery for Skull Base Meningiomas
Cohen‐Inbar, O., Lee, C.-C., Schlesinger, D. J., Xu, Z., & Sheehan, J. P. (2015) · Neurosurgery · doi:10.1227/neu.0000000000001045 · Cited by 55
“8 10/15 19%/62% Mirimanoff et al(57) 1985 225 N/A 11 7%/63% 20%/45% 32%/9% Simpson et al(19) 1957 1241 60 (6-240) 36 9% (Simpson = 1), 19% (Simpson = 2),”
Influential
Carbon ion radiotherapy in pancreatic cancer: A review of clinical data
Liermann, J., Shinoto, M., Syed, M., Debus, J., Herfarth, K. K., & Naumann, P. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.05.012 · Cited by 56
The Role of Irradiated Heart and Left Ventricular Volumes in Heart Failure Occurrence After Childhood Cancer
Mansouri, I., Allodji, R. S., Hill, C., El‐Fayech, C., Pein, F. J. L., Diallo, S., Schwartz, B., Vu‐Bezin, G., Veres, C., Souchard, V., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1376 · Cited by 54
Combining handcrafted features with latent variables in machine learning for prediction of radiation‐induced lung damage
Cui, S., Luo, Y., Tseng, H., Haken, R. K. T., & Naqa, I. E. (2019) · Medical Physics · doi:10.1002/mp.13497 · Cited by 55
“This is particularly important in the case of radiation-induced lung damage [8], which is a complex disease that manifests in up to 30% of thoracic irradiations in the forms of acute inflammatory radiation pneumonitis (RP) and subsequent chronic pulmonary fibrosis [9].”
Background
Trial Watch: Radioimmunotherapy for oncological indications
Bloy, N., Pol, J. G., Manic, G., Vitale, I., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954929 · Cited by 56
Feasibility of extreme dose escalation for glioblastoma multiforme using 4π radiotherapy
Nguyen, D. T. D., Rwigema, J. M., Yu, V., Kaprealian, T. B., Kupelian, P. A., Selch, M. T., Lee, P. P., Low, D. A., & Sheng, K. (2014) · Radiation Oncology · doi:10.1186/s13014-014-0239-x · Cited by 53
“In addition, it had been observed in brain SRS studies that there is a rapid rise of brain necrosis when the volume of brain receiving 12 Gy or greater (V12) is more than 5– 10 cm(3) [17].”
Background
INTRAGO: intraoperative radiotherapy in glioblastoma multiforme – a Phase I/II dose escalation study
Giordano, F. A., Brehmer, S., Abo‐Madyan, Y., Welzel, G., Sperk, E., Keller, A., Schneider, F. W., Clausen, S., Herskind, C., Schmiedek, P., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-992 · Cited by 57
“5 Gy (brain stem) are commonly accepted in LINACbased EBRT according to the QUANTEC (Quantitative Analyses of Normal Tissue Effects in the Clinic) recommendations [26].”
Method
Predictors of High-grade Esophagitis After Definitive Three-dimensional Conformal Therapy, Intensity-modulated Radiation Therapy, or Proton Beam Therapy for Non-small cell Lung Cancer
Gomez, D. R., Tucker, S. L., Martel, M. K., Mohan, R., Balter, P. A., Guerra, J. L. L., Liu, H., Komaki, R. U., Cox, J. D., & Liao, Z. X. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.01.071 · Cited by 53
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
Zamboglou, C., Spohn, S. K. B., Adebahr, S., Huber, M., Kirste, S., Sprave, T., Gratzke, C., Chen, R. C., Carl, E., Weber, W., et al. (2021) · Cancers · doi:10.3390/cancers13225795 · Cited by 52
“However, due to the proximity to the rectum and bladder, an unlimited dose escalation to the whole prostatic gland with external beam RT would entail a high risk of severe toxicity [30].”
Background
DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis
Bernhardt, D., König, L., Grosu, A., Wiestler, B., Rieken, S., Wick, W., Gempt, J., Krieg, S. M., Schmidt‐Graf, F., Sahm, F., et al. (2022) · Strahlentherapie und Onkologie · doi:10.1007/s00066-022-01994-3 · Cited by 52
“QUANTEC data reveal a dose–response relationship in the brain where the incidence of RN increases from 3% with a Dmax <60Gy to 5% at Dmax= 72Gy [22].”
Background
Relationship Between Radiation-Induced Apoptosis of T Lymphocytes and Chronic Toxicity in Patients With Prostate Cancer Treated by Radiation Therapy: A Prospective Study
Foro, P., Algara, M., Lozano, J., Rodríguez, N., Sanz, X., Torres, E., Carles, J., Reig, A., Membrive, I., Quera, J., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.01.002 · Cited by 52
Identification of a rectal subregion highly predictive of rectal bleeding in prostate cancer IMRT
Dréan, G., Acosta, O., Ospina, J. D., Fargeas, A., Lafond, C., Corrégé, G., Lagrange, J.-L., Créhange, G., Simon, A., Haigron, P., et al. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.04.023 · Cited by 52
The radiation dose tolerance of the brachial plexus: A systematic review and meta-analysis
Yan, M., Kong, W., Kerr, A., & Brundage, M. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.06.006 · Cited by 52
“The QUANTEC studies, which aimed to provide updated tolerances in light of radiotherapy advancement, did not specify guidelines for brachial plexus dose tolerance [7].”
Background
NRG Oncology Assessment of Artificial Intelligence Deep Learning–Based Auto-segmentation for Radiation Therapy: Current Developments, Clinical Considerations, and Future Directions
Rong, Y., Chen, Q., Fu, Y., Yang, X., Al‐Hallaq, H., Wu, Q., Yuan, L., Xiao, Y., Cai, B., Latifi, K., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.10.033 · Cited by 58
Feasibility of MR-only proton dose calculations for prostate cancer radiotherapy using a commercial pseudo-CT generation method
Maspero, M., van den Berg, C. A. T., Landry, G., Belka, C., Parodi, K., Seevinck, P. R., Raaymakers, B. W., & Kurz, C. (2017) · Physics in Medicine and Biology · doi:10.1088/1361-6560/aa9677 · Cited by 51
Grand challenges for medical physics in radiation oncology
Fiorino, C., Jeraj, R., Clark, C. H., Garibaldi, C., Georg, D., Muren, L. P., van Elmpt, W., Bortfeld, T. R., & Jornet, N. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.10.001 · Cited by 51
“High-impact examples are the quantification of dose-volume effects based on clinical data, being relevant in everyday radiotherapy planning and optimization [48,49] as well as the adaptation and use of fractionation models aimed to translate physical doses into biologically equivalent doses for tumors [50].”
Background
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates
Cheal, S. M., Xu, H., Guo, H.-F., Lee, S., Punzalan, B. J., Chalasani, S., Fung, E. K., Jungbluth, A. A., ZANZONICO, P. B., Carrasquillo, J. A., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3254-8 · Cited by 50
“Based on human normal-tissue radiation dose tolerance estimates derived from clinical observations [35], the MTDs are 250 cGy for bone marrow, 1,500 cGy for lung, 3,000 cGy for liver, and 2,000 cGy for kidney.”
Method
Increasing the Therapeutic Ratio of Stereotactic Ablative Radiotherapy by Individualized Isotoxic Dose Prescription
Zindler, J. D., Thomas, C. R., Hahn, S. M., Hoffmann, A. L., Troost, E. G. C., & Lambin, P. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv305 · Cited by 50
Dose accumulation for MR-guided adaptive radiotherapy: From practical considerations to state-of-the-art clinical implementation
McDonald, B. A., Zachiu, C., Christodouleas, J. P., Naser, M. A., Ruschin, M., Sonke, J., Thorwarth, D., Létourneau, D., Tyagi, N., Tadic, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1086258 · Cited by 49
Increased risk of death due to heart disease after radiotherapy for esophageal cancer.
Frandsen, J. E., Boothe, D. L., Gaffney, D. K., Wilson, B. D., & Lloyd, S. A. J. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2015.040 · Cited by 50
“Current cooperative group esophageal chemoradiation protocols recommend limiting the volume receiving 40 Gy to less than 50%, and the mean heart dose to less than 27 Gy (27), which is expected to limit the rate of pericarditis to less than approximately 15% (28).”
Background
Assessment and management of radiotherapy induced toxicity in older patients
O’Donovan, A., Leech, M., & Gillham, C. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.07.001 · Cited by 51
Clinical Outcomes and Dosimetric Considerations Using Stereotactic Body Radiotherapy for Abdominopelvic Tumors
Barney, B. M., Olivier, K. R., Macdonald, O. K., Santos, L. E. F. D. L., Miller, R. C., & Haddock, M. G. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31821f876a · Cited by 48
A tumor control probability model for anal squamous cell carcinoma
Muirhead, R., Partridge, M., & Hawkins, M. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.07.014 · Cited by 48
“Details including definition of local control, overall survival, censorship and exclusion of patients; required to adhere to guidance on meta-analysis was not available [39–41].”
Background
Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer
Cheal, S. M., Fung, E. K., Patel, M., Xu, H., Guo, H.-F., ZANZONICO, P. B., Monette, S., Wittrup, K. D., Cheung, N. V., & Larson, S. M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193250 · Cited by 48
“We chose these benchmarks based on clinical human normal-tissue radiation dose tolerance estimates (11), as well as experience gleaned from radiopeptide treatments and related toxicities in humans (1).”
Method
Multidisciplinary Approach to Spinal Metastases and Metastatic Spinal Cord Compression—A New Integrative Flowchart for Patient Management
Esperança‐Martins, M., Roque, D., Barroso, T., Abrunhosa-Branquinho, A. N., Belo, D., Simas, N., & Costa, L. (2023) · Cancers · doi:10.3390/cancers15061796 · Cited by 49
“Neurological complications such as myelopathy from radiation are late, rare events and are normally mitigated during RT planning [52].”
Background
Use of gEUD for predicting ear and pituitary gland damage following proton and photon radiation therapy
Marzi, L. D., Feuvret, L., Boulé, T. P., Habrand, J. L., Martin, F., Calugaru, V., Fournier‐Bidoz, N., Ferrand, R., & Mazal, A. (2015) · British Journal of Radiology · doi:10.1259/bjr.20140413 · Cited by 47
Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68 Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference
Zamboglou, C., Sachpazidis, I., Koubar, K., Drendel, V., Wiehle, R., Kirste, S., Mix, M. D., Schiller, F., Mavroidis, P., Meyer, P. T., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.04.021 · Cited by 47
“However, due to the proximity to rectum and bladder an unlimited dose escalation to the whole prostatic gland with external beam RT would entail an unacceptably high risk of severe toxicity [2].”
BackgroundMethod
The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients
Güler, O. C., Engels, B., Önal, C., Everaert, H., den Begin, R. V., Gevaert, T., & Ridder, M. D. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1736-9 · Cited by 47
Dose or ‘LET’ painting – What is optimal in particle therapy of hypoxic tumors?
Malinen, E., & Søvik, Å. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1062540 · Cited by 46
“Normal tissues and their associated complication probabilities [22] were not explicitly included in the present work.”
Background
Quantification of dose uncertainties in cumulated dose estimation compared to planned dose in prostate IMRT
Nassef, M., Simon, A., Cazoulat, G., Duménil, A., Blay, C., Lafond, C., Acosta, O., Balosso, J., Haigron, P., & de Crevoisier, R. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.03.007 · Cited by 46
“Reference RTOG/QUANTEC rectum wall and bladder wall DVH points were also analyzed [25].”
Method
Thyroid V50 Highly Predictive of Hypothyroidism in Head-and-Neck Cancer Patients Treated With Intensity-modulated Radiotherapy (IMRT)
Sachdev, S., Refaat, T., Bacchus, I. D., Sathiaseelan, V., & Mittal, B. B. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000165 · Cited by 46
“The more recent Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) guidelines did not include thyroid parameters.(31) Although our proposed constraints should be independently validated, we provide a clinically applicable dosimetric parameter derived from a relatively homogenous patient population…”
Background
Proton versus photon radiation therapy for patients with high‐risk neuroblastoma: The need for a customized approach
Hill‐Kayser, C. E., Tochner, Z. A., Both, S., Lustig, R. A., Reilly, A. F., Balamuth, N., Womer, R. B., Maris, J. M., Grupp, S. A., & Bagatell, R. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24606 · Cited by 46
“These constraints are based on those associated with less than 5% risk of normal organ damage in the adult population within the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) publication; however, as noted by those authors, normal organ tolerance in children is not well understood [16,17].”
Background
Dose-volume effects on brainstem dose tolerance in radiosurgery
Xue, J., Goldman, H. W., Grimm, J., LaCouture, T. A., Chen, Y., Hughes, L., & Yorke, E. D. (2012) · Journal of neurosurgery · doi:10.3171/2012.7.gks12962 · Cited by 45
Self-citation
SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings
Hessissen, L., Parkes, J., Amayiri, N. Y., Mushtaq, N., Sirachainan, N., Anacak, Y., Mitra, D., Figaji, A. A., Meeteren, A. Y. N. S., Sullivan, M. J., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26737 · Cited by 45
Optimal fractionation in radiotherapy with multiple normal tissues
Saberian, F., Ghate, A., & Kim, M. (2015) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqv015 · Cited by 45
“2 Mean dose constraints for parallel normal tissue Let M2 ⊆M be the set of indices of parallel normal tissues with mean dose constraints; these are the normal tissues where a sufficiently small portion can be damaged without affecting the organ function [43].”
BackgroundInfluential
Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations
Ebert, M. A., Gulliford, S., Acosta, O., de Crevoisier, R., McNutt, T., Heemsbergen, W. D., Witte, M. G., Palma, G., Rancati, T., & Fiorino, C. (2021) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ac0681 · Cited by 44
“In 2010, theQuantitative Analysis of Normal Tissue Effects in theClinic (QUANTEC) review summarised the three-dimensional dose/volume/ outcome data to update and refine the related normal tissue tolerance guidelines (Marks et al 2010), initially provided by Emami et al (1991).”
Method
Dose constraints in breast cancer radiotherapy. A critical review
Rose, F. D., Santis, M. C. D., Lucidi, S., Colciago, R. R., Marino, L., Cucciarelli, F., Rocca, E. L., Pressa, F. D., Lohr, F., Vanoni, V., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110591 · Cited by 51
Mechanisms of radiation-induced sensorineural hearing loss and radioprotection
Mujica‐Mota, M. A., Lehnert, S., Dević, S., Gasbarrino, K., & Daniel, S. J. (2014) · Hearing Research · doi:10.1016/j.heares.2014.03.003 · Cited by 43
“Recent efforts by Marks et al. (2010) estimated a dose-volume limit for hearing (at 4 kHz frequency) of 45 Gy for fractionated RT and 14 Gy for stereotactic radiosurgery (single dose).”
Overview on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant radiotherapy for breast cancer
Meattini, I., GUENZI, M., Fozza, A., Vidali, C., Rovea, P., Meacci, F., & Livi, L. (2016) · Breast Cancer · doi:10.1007/s12282-016-0694-3 · Cited by 45
“QUANTEC [89] D mean \26 Gy \15 % pericarditis”
BackgroundMethodInfluential
Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients
Schmitt, N. C., & Page, B. R. (2017) · International Journal of Audiology · doi:10.1080/14992027.2017.1353710 · Cited by 43
“With regard to radiotherapyrelated dose volume constraints, for patients with base of skull or nasopharynx tumours we follow QUANTEC recommendations (Marks et al, 2010) for 30% cochlea volume getting less than 45 Gy.”
Background
The Impact of Pelvic Nodal Radiotherapy on Hematologic Toxicity: A Systematic Review with Focus on Leukopenia, Lymphopenia and Future Perspectives in Prostate Cancer Treatment
Iorio, G. C., Spieler, B. O., Ricardi, U., & Pra, A. D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103497 · Cited by 43
64Cu-SAR-Bombesin PET-CT Imaging in the Staging of Estrogen/Progesterone Receptor Positive, HER2 Negative Metastatic Breast Cancer Patients: Safety, Dosimetry and Feasibility in a Phase I Trial
Wong, K., Sheehan‐Dare, G., Nguyen, A., Ho, B., Liu, V., Lee, J., Brown, L. J., Dear, R. F.-G., Chan, L., Sharma, S., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15070772 · Cited by 42
Artificial intelligence to predict outcomes of head and neck radiotherapy
Bang, C., Bernard, G., Le, W., Lalonde, A., Kadoury, S., & Bahig, H. (2023) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2023.100590 · Cited by 42
“However, the predictive power of currently models is largely limited by the lack of integration of patient-specific risk factors [40 41] and omission of the inclusion of radiomic features despite studies having shown their relevance [38].”
Background
A data‐mining framework for large scale analysis of dose‐outcome relationships in a database of irradiated head and neck cancer patients
Robertson, S. P., Quon, H., Kiess, A. P., Moore, J. A., Yang, W., Cheng, Z., Afonso, S. L., Allen, M., Richardson, M., Choflet, A., et al. (2015) · Medical Physics · doi:10.1118/1.4922686 · Cited by 42
Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report
Messer, J. A., Ekinci, E., Patel, T. A., & Teh, B. S. (2019) · Reports of Practical Oncology & Radiotherapy · doi:10.1016/j.rpor.2019.03.001 · Cited by 42
Adjuvant breast radiotherapy using a simultaneous integrated boost: Clinical and dosimetric perspectives
Alford, S., Prassas, G., Vogelesang, C. R., Leggett, H. J., & Hamilton, C. S. (2013) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/j.1754-9485.2012.02473.x · Cited by 42
Comparison and Limitations of DVH-Based NTCP Models Derived From 3D-CRT and IMRT Data for Prediction of Gastrointestinal Toxicities in Prostate Cancer Patients by Using Propensity Score Matched Pair Analysis
Troeller, A., Yan, D., Marina, O., Schulze, D., Alber, M. L., Parodi, K., Belka, C., & Söhn, M. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.09.046 · Cited by 41
Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control
Chajon, É., Lafond, C., Louvel, G., Castelli, J., Williaume, D., Henry, O., Jégoux, F., Vauléon, É., Manens, J.-P., Prisé, É. L., et al. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-132 · Cited by 41
“The following OAR dose constraints were used [14]: brainstem and spinal cord maximum doses (D2%) were 50Gy and 45Gy, respectively; for the parotid glands, mean dose (D mean) was <26Gy or the maximum dose received by 50% of the volume was <30Gy; for the SMG, D mean was ≤39Gy; for OC (defined as previously described by…”
Background
Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy – a single-centre experience
Henkenberens, C., Janssen, S., Lavae-Mokhtari, M., Leni, K., Meyer, A., Christiansen, H., Bremer, M., & Dickgreber, N. J. (2016) · Radiation Oncology · doi:10.1186/s13014-016-0580-3 · Cited by 41
“tissue constraints [22]; particularly, RP is one of the most significant dose-limiting factors in the radiation treatment of non-small cell lung cancer (NSCLC; [3, 23]).”
Background
What is the best way to radiate the prostate in 2016?
Moon, D. H., Efstathiou, J. A., & Chen, R. C. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.06.002 · Cited by 41
Impact on quality of life of IMRT versus 3-D conformal radiation therapy in head and neck cancer patients: A case control study
Abel, E., Silander, E. M., Nyman, J., Bove, M., Johansson, L., Björk‐Eriksson, T., & Hammerlid, E. B. (2017) · Advances in Radiation Oncology · doi:10.1016/j.adro.2017.05.002 · Cited by 41
“2 Gy, which approaches the recommended threshold doses reported by both the Quantitative Analysis of Normal Tissue effects in the Clinic review and a separate analysis from the PARSPORT trial.(27,28) Further DDP optimization and improvements in delineation methods using advanced imaging technologies (eg, magnetic reso…”
Method
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
Cheal, S. M., Xu, H., Guo, H.-F., Patel, M., Punzalan, B. J., Fung, E. K., Lee, S., Bell, M. M., Singh, M., Jungbluth, A. A., et al. (2018) · Theranostics · doi:10.7150/thno.26585 · Cited by 41
“Based on estimated maximum tolerated doses of 250 and 2000 cGy for blood (bone marrow) and kidney, respectively [17], the estimated maximum tolerated activity is ~180 MBq, with blood (bone marrow) as the dose-limiting tissue (TI for blood: 28).”
Background
Rectum-spacer related acute toxicity – endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers
Schörghofer, A., Drerup, M., Kunit, T., Lusuardi, L., Holzinger, J., Karner, J., Groher, M., Zoubek, C., Forstner, R., Sedlmayer, F., et al. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1248-6 · Cited by 41
NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy
Hansen, C. R., Friborg, J., Jensen, K., Samsøe, E., Johnsen, L., Zukauskaite, R., Grau, C., Maare, C., Johansen, J., Primdahl, H., et al. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1654129 · Cited by 41
“, which need to be understood and managed in order for the clinical implementation to be safe [24].”
Background
Comparison of two different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency
Wolf, F., Gaisberger, C., Ziegler, I., Krenn, E., Scherer, P., Hruby, S., Schätz, T., Forstner, R., Holzinger, J., Vaszi, A., et al. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.07.027 · Cited by 41
“Since a rectal dose beyond 70 Gy is a predictor for rectal toxicity [4], the rectum remains to be the primary organ at risk (OAR) [5] in EBRT, warranting research into more efficient rectum sparing strategies.”
Background
Statistical Validation of Normal Tissue Complication Probability Models
Xu, C., van der Schaaf, A., Veld, A. A. V., Langendijk, J. A., & Schilstra, C. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.02.022 · Cited by 40
Treatment of MRI-Diagnosed Trigeminal Peripheral Nerve Sheath Tumors by Stereotactic Radiotherapy in Dogs
Hansen, K. S., Zwingenberger, A. L., Théon, A. P., Pfeiffer, I., & Kent, M. S. (2016) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.13970 · Cited by 40
Clinical parameters for predicting radiation-induced liver disease after intrahepatic reirradiation for hepatocellular carcinoma
Huang, Y., Chen, S.-W., Fan, C.-C., Ting, L., Kuo, C., & Chiou, J.-F. (2016) · Radiation Oncology · doi:10.1186/s13014-016-0663-1 · Cited by 40
Normofractionated stereotactic radiotherapy versus CyberKnife-based hypofractionation in skull base meningioma: a German and Italian pooled cohort analysis
Alfredo, C., Carolin, S., Acker, G., Kluge, A. K., Pontoriero, A., Cacciola, A., Pergolizzi, S., Germanò, A., Badakhshi, H., Kufeld, M., et al. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1397-7 · Cited by 40
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
Chicheportiche, A., Ben‐Haim, S., Grozinsky‐Glasberg, S., Oleinikov, K., Meirovitz, A., Gross, D. J., & Godefroy, J. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-0273-8 · Cited by 40
Methodological Development of Combination Drug and Radiotherapy in Basic and Clinical Research
Chargari, C., Lévy, A., Paolettí, X., Soria, J., Massard, C., Weichselbaum, R. R., & Deutsch, É. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4155 · Cited by 40
“The average acceptable rate of major side effects after radiotherapy, especially late effects, is less than 5%, as described in the classic Emami tolerance parameters (68), which have been revisited in the more recent Quantec data (69).”
Background
Spatially Fractionated Radiotherapy in the Era of Immunotherapy
McMillan, M. T., Khan, A. J., Powell, S. N., Humm, J. L., Deasy, J. O., & Haimovitz‐Friedman, A. (2024) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2024.04.002 · Cited by 43
Self-citation
Dosimetric study of volumetric arc modulation with RapidArc and intensity-modulated radiotherapy in patients with cervical cancer and comparison with 3-dimensional conformal technique for definitive radiotherapy in patients with cervical cancer
Guy, J., Falk, A. T., Auberdiac, P., Cartier, L., Vallard, A., Ollier, É., Trone, J., Khodri, M., Chargari, C., & Magné, N. (2015) · Medical dosimetry · doi:10.1016/j.meddos.2015.06.002 · Cited by 39
Dosimetric and efficiency comparison of high-dose radiotherapy for esophageal cancer: volumetric modulated arc therapy versus fixed-field intensity-modulated radiotherapy
Lin, C., Huang, W., Jen, Y., Chen, C.-M., Su, Y.-F., Chao, H. L., & Lin, C. (2013) · Diseases of the Esophagus · doi:10.1111/dote.12144 · Cited by 39
Effects of changing modulation and pitch parameters on tomotherapy delivery quality assurance plans
Binny, D., Lancaster, C. M., Harris, S., & Sylvander, S. R. (2015) · Journal of Applied Clinical Medical Physics · doi:10.1120/jacmp.v16i5.5282 · Cited by 39
“1 (e) and (f), the optimizer in the case of reduced modulation factors can cause the dose constraints to be out of tolerance delivering very high doses to OAR, as per published data(12,13,14) and compromising the PTV coverage.”
BackgroundMethod
Effect of the Maximum Dose on White Matter Fiber Bundles Using Longitudinal Diffusion Tensor Imaging
Zhu, T., Chapman, C. H., Tsien, C. I., Kim, M. H., Spratt, D. E., Lawrence, T. S., & Cao, Y. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.07.010 · Cited by 39
“In current clinical practice, limited guidelines (33) are available to avoid necrosis and to spare the brainstem and optic nerves and chiasm.”
Target position uncertainty during visually guided deep-inspiration breath-hold radiotherapy in locally advanced lung cancer
Rydhög, J. S., de Blanck, S. R., Josipović, M., Jølck, R. I., Larsen, K. R., Clementsen, P. F., Andersen, T. L., Poulsen, P. R., Persson, G. F., & af Rosenschöld, P. M. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.02.003 · Cited by 39
Selection of external beam radiotherapy approaches for precise and accurate cancer treatment
Shirato, H., Le, Q., Kobashi, K., Prayongrat, A., Takao, S., Shimizu, S., Giaccia, A. J., Xing, L., & Umegaki, K. (2018) · Journal of Radiation Research · doi:10.1093/jrr/rrx092 · Cited by 40
“A generalized equivalent uniform dose (gEUD) has been shown to be useful when comparing different dose fractionation schedules in the 3DRTP era [40, 41].”
Background
Pericardial disease after breast cancer radiotherapy
Marinko, T. (2018) · Radiology and Oncology · doi:10.2478/raon-2018-0035 · Cited by 41
Deep Seated Tumour Treatments With Electrons of High Energy Delivered at FLASH Rates: The Example of Prostate Cancer
Sarti, A., Maria, P. D., Battistoni, G., Simoni, M. D., Felice, C. D., Dong, Y., Fischetti, M., Franciosini, G., Marafini, M., Marampon, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.777852 · Cited by 39
“Dosimetric endpoints are either expressed as the fraction of volume (VXX) that absorbs a given amount of dose (XX Gy), or as the value of the maximum absorbed dose (and the associated volume) (29) and are shown in Table 2 for all the OARs considered in a prostate treatment.”
BackgroundMethod
The tolerance of gastrointestinal organs to stereotactic body radiation therapy: what do we know so far?
Thomas, T. O., Hasan, S., Small, W. C., Herman, J. M., Lock, M. I., Kim, E. Y., Mayr, N. A., Teh, B. S., & Lo, S. S.-M. (2014) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.024 · Cited by 39
“of normal tissue effects in the clinic) (4) described the dose”
BackgroundMethodInfluential
Prediction of rectum and bladder morbidity following radiotherapy of prostate cancer based on motion-inclusive dose distributions
Thor, M., Bentzen, L., Hysing, L. B., Ekanger, C., Helle, S. I., Karlsdóttir, Á., & Muren, L. P. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.03.029 · Cited by 38
Interactive Decision-Support Tool for Risk-Based Radiation Therapy Plan Comparison for Hodgkin Lymphoma
Brodin, N. P., Maraldo, M. V., Aznar, M. C., Vogelius, I. R., Petersen, P. M., Bentzen, S. M., & Specht, L. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.10.028 · Cited by 38
“used normal tissue dose constraints (9) will almost inevitably be met by any HL dose plan.”
BackgroundSelf-citation
Proton vs photon: A model-based approach to patient selection for reduction of cardiac toxicity in locally advanced lung cancer
Teoh, S., Fiorini, F., George, B., Vallis, K. A., & den Heuvel, F. V. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.06.032 · Cited by 38
“Most NTCP models rely only on dose parameters to estimate complication probabilities [14] and this limits their predictive power [15].”
Background

Authors: Marks, L. B., Yorke, E. D., Jackson, A., Ten Haken, R. K., Constine, L. S., Eisbruch, A., Bentzen, S. M., Nam, J., & Deasy, J. O.
Affiliations: University of North Carolina at Chapel Hill (US)
Memorial Sloan Kettering Cancer Center (US)
University of Rochester Medicine (US)
University of Michigan (US)
University of Wisconsin–Madison (US)
Washington University in St. Louis (US)
Corresponding author: Marks, Lawrence B.
ORCID: Marks, Lawrence B.
Yorke, Ellen D.
Jackson, Andrew
Constine, Louis S.
Eisbruch, Avraham
Bentzen, Søren M.
Nam, Jiho
Deasy, Joseph O.
Venue: International Journal of Radiation Oncology*Biology*Physics
Publisher: Elsevier BV
Published: 2010-03
Volume: 76
Issue: 3
Pages: S10-S19
ISSN: 0360-3016 (ISSN-L)
DOI: 10.1016/j.ijrobp.2009.07.1754
PMC: PMC4041542
OpenAlex: W2046701188
Cited by: 1,826
References: 30
Citations by year: 2026: 92 · 2025: 110 · 2024: 125 · 2023: 132 · 2022: 130 · 2021: 160 · 2020: 138 · 2019: 146 · 2018: 164 · 2017: 122 · 2016: 108 · 2015: 102 · 2014: 112 · 2013: 87 · 2012: 55
FWCI: 56.07
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: International Journal of Radiation Oncology*Biology*Physics (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Lance Armstrong Foundation
Armstrong Foundation
National Institutes of Health
National Cancer Institute (CA69579, R29CA069579, R29CA085181, R01CA069579, R01CA129182, R01CA085181, CA85181)
Topics: Physical Sciences › Physics and Astronomy › Radiation › Advanced Radiotherapy Techniques
Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
Keywords: normal tissue complication probability, QUANTEC, normal tissue tolerance, NTCP models
MeSH terms: Adult, Child, Dose-Response Relationship, Radiation, Humans, Models, Biological, Organ Specificity, Radiation Injuries, Radiation Tolerance, Models, Statistical, Practice Guidelines as Topic, Radiation Oncology, Dose Fractionation, Radiation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Use of Normal Tissue Complication Probability Models in the Clinic

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks